Taysha Gene Therapies (TSHA) Treasury Shares (2020)

Taysha Gene Therapies has reported Treasury Shares for 7 years, with the latest figure at $10.9 million in Q1 2026.

• Quarterly Treasury Shares rose 74.29% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 74.29% YoY) and the FY2025 annual result came in at $6.3 million, up 38.73% from the prior year.
• Treasury Shares climbed to $10.9 million in Q1 2026 per TSHA's latest filing, from $6.3 million in the prior quarter.
• Over five years, Treasury Shares peaked at $10.9 million in Q1 2026 and troughed at $85494.0 in Q4 2022.
• A 5-year average of $3.5 million and a median of $3.2 million in 2022 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares plunged 95.47% in 2022, then jumped 1112.97% in 2024.
• Over 5 years, Treasury Shares stood at $85494.0 in 2022, then surged by 338.68% to $375044.0 in 2023, then surged by 1112.97% to $4.5 million in 2024, then surged by 38.73% to $6.3 million in 2025, then surged by 72.37% to $10.9 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $10.9 million, $6.3 million, and $6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.